First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187.
N Engl J Med. 2020.
PMID: 33207094
Clinical Trial.